Seer, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 12, 2026 at 3:30 PM GMT+3 3 min read

Seer, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Revenue grew $0.3 million sequentially from Q1, reaching a total of $3.1 million for the quarter reflects early commercial stabilization despite persistent academic and government funding pressures.
Management attributes the current revenue level to the 'nascent' stage of the deep proteomics market, where scientific validation precedes commercial inflection.
The platform is being positioned as a critical data source for AI foundation models, providing 7x more data points and 11x more peptide-level measurements than high-plex targeted assays.
Third-party validation from Roche and Nature Genetics studies confirms the Proteograph's superior depth and reproducibility compared to affinity-based competitors like Olink and SomaLogic.
Strategic focus has shifted toward large accounts and population-scale studies to drive meaningful, recurring revenue through high-volume consumable pull-through.
The company is aggressively defending its intellectual property, citing recent favorable rulings from the U.S. PTAB and European Patent Office against competitors.

Outlook and Strategic Initiatives

Full-year 2026 revenue guidance of $16 million to $18 million is reaffirmed, targeting revenue growth in the second half of 2026 to meet full-year revenue guidance of $16 million to $18 million.
Guidance assumes that the challenging academic and government funding environment will persist through the remainder of 2026.
Management expects the release of PRECISE-SG-100K data at the HUPO conference in September to serve as a catalyst for large-scale biobank commitments.
The commercial ramp is expected to build over several months as the new Chief Commercial Officer optimizes infrastructure for lean execution and capital discipline.
Current cash reserves of $209.5 million are deemed sufficient to reach cash flow breakeven without requiring additional external capital.

Operational and Risk Factors

The share repurchase program has reduced net total common shares outstanding by approximately 15% to address perceived stock price dislocation.
Gross margins improved 1,300 basis points sequentially to 49%, though management expects continued quarterly variability based on product mix.
Related party revenue from PrognomIQ has declined to nominal levels as they pivot toward lab-developed tests rather than discovery work.
Legal and professional service expenses remained elevated due to ongoing patent infringement litigation and intellectual property defense.

Q&A Session Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Instrument placement trends and SIP program conversions

Management noted a shift in placement mix, with 1/3 of instruments coming from the Seer Insights Program (SIP) and 1/3 from previous service customers.
The transition reflects a maturing pipeline where initial service projects are successfully converting into direct instrument ownership.

The role of deep proteomics in training AI models

Omid Farokhzad emphasized that untargeted approaches are uniquely suited for AI because they capture protein variants and 'undiscovered content' at scale.
Unlike targeted assays, Seer's platform provides the peptide-level resolution necessary for AI to recognize complex biological patterns in health and disease.

Academic funding dynamics across different therapeutic areas

Management highlighted a divergence in funding, noting that while neuroscience budgets have increased by 7%, other areas remain flat or down.
Seer continues to observe significant hesitancy and grant delays among its core academic customer base outside of the neurology space.